Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabometyx plus Keytruda in recurrent or metastatic cervical cancer
NCT04230954Phase 2Terminated
- Sponsor
- University of South Alabama
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in Cervical Cancer (CC), sponsored by University of South Alabama. Started Apr 2020; status: terminated.
02
Drugs
cabozantinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04230954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230954.